Characterization of C69R variant HBsAg: effect on binding to anti-HBs and the structure of virus-like particles
- PMID: 26175067
- DOI: 10.1007/s00705-015-2515-y
Characterization of C69R variant HBsAg: effect on binding to anti-HBs and the structure of virus-like particles
Abstract
Several variants of the major "a" determinant of the HBsAg, the main target of HBV neutralization by antibodies, have been described. However, mutations outside this region have not been as thoroughly investigated. During the genotyping of HBV from Tunisian patients with chronic hepatitis B, we identified a variant with a C69R substitution in the cytosolic loop of the S protein, resulting in a change in the hydrophobicity profile compared to the wild-type HBsAg. Wild-type and mutant HBsAgs were produced in Saccharomyces cerevisiae and recombinant proteins were tested for their ability to correctly self-assemble into virus-like particles (VLPs), and their ability to bind to HBs antibodies. The C69R substitution resulted in a decrease in binding to commercial anti-HBs antibodies, and although the variant appeared to assemble properly into VLPs, the average size of the particles was larger than that of the wild-type HBsAg. Prediction of the tertiary structure of the C69R mutant revealed a change in the first (aa 60-70) and the second loop (aa 110 to 120) compared to the wild-type protein. Furthermore, we showed by an isothermal titration calorimetry assay that the interaction between the wild-type HBsAg and the anti-HBs antibody was exothermic, whereas that with the mutant C69R was endothermic, indicating an effect on the binding affinity.
Similar articles
-
Characterization of a novel hepatitis B virus mutant: demonstration of mutation-induced hepatitis B virus surface antigen group specific "a" determinant conformation change and its application in diagnostic assays.Transfus Med. 2001 Oct;11(5):355-62. doi: 10.1046/j.1365-3148.2001.00323.x. Transfus Med. 2001. PMID: 11696228
-
Biological significance of amino acid substitutions in hepatitis B surface antigen (HBsAg) for glycosylation, secretion, antigenicity and immunogenicity of HBsAg and hepatitis B virus replication.J Gen Virol. 2010 Feb;91(Pt 2):483-92. doi: 10.1099/vir.0.012740-0. Epub 2009 Oct 7. J Gen Virol. 2010. PMID: 19812261
-
Mutations in hepatitis B virus DNA from patients with coexisting HBsAg and anti-HBs.J Clin Virol. 2011 Nov;52(3):198-203. doi: 10.1016/j.jcv.2011.07.011. Epub 2011 Aug 15. J Clin Virol. 2011. PMID: 21840251
-
Acute hepatitis B caused by a vaccine-escape HBV strain in vaccinated subject: sequence analysis and therapeutic strategy.J Clin Virol. 2015 Jan;62:89-91. doi: 10.1016/j.jcv.2014.11.029. Epub 2014 Nov 29. J Clin Virol. 2015. PMID: 25542480 Review.
-
Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact.J Clin Virol. 2005 Feb;32(2):102-12. doi: 10.1016/j.jcv.2004.10.008. J Clin Virol. 2005. PMID: 15653412 Review.
Cited by
-
Comparative purification and characterization of hepatitis B virus-like particles produced by recombinant vaccinia viruses in human hepatoma cells and human primary hepatocytes.PLoS One. 2019 Feb 22;14(2):e0212800. doi: 10.1371/journal.pone.0212800. eCollection 2019. PLoS One. 2019. PMID: 30794666 Free PMC article.
-
Evolution of full-length genomes of HBV quasispecies in sera of patients with a coexistence of HBsAg and anti-HBs antibodies.Sci Rep. 2017 Apr 6;7(1):661. doi: 10.1038/s41598-017-00694-8. Sci Rep. 2017. PMID: 28386078 Free PMC article.
-
Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery.Vaccines (Basel). 2023 Feb 18;11(2):479. doi: 10.3390/vaccines11020479. Vaccines (Basel). 2023. PMID: 36851356 Free PMC article. Review.
-
New Gene Variants Associated with the Risk of Chronic HBV Infection.Virol Sin. 2020 Aug;35(4):378-387. doi: 10.1007/s12250-020-00200-x. Epub 2020 Apr 15. Virol Sin. 2020. PMID: 32297155 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical